Clinical Trial Update: A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1B study assessing safety and tolerability of combining canakinumab and tislelizumab with nab-paclitaxel and gemcitabine as neoadjuvant therapy for pancre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Canakinumab (canakinumab)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Pancreatic Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING